Sia Daneshmand, Urologic Oncology Fellowship Director at University of Southern California shared on X:
“Excited to share our latest review in Nature Reviews Urology.
As the landscape of bladder-preserving therapies rapidly expands, the next frontier in NMIBC is not simply developing new agents but understanding how best to combine and sequence them to maximize durable responses and minimize progression.”
Main conclusions of the article
- Combination therapy: For patients with BCG-unresponsive non-muscle-invasive bladder cancer, combining treatments may offer better and more durable disease control than single-agent therapies, which can be limited by treatment resistance.
- Bladder preservation: Combining therapies could provide alternatives to radical cystectomy while maintaining cancer control and avoiding major surgery.
- Multiple treatment combinations: Strategies include combining intravesical chemotherapy, immunotherapy, gene therapy, BCG, and radiotherapy to target cancer through complementary mechanisms.
- Further research is needed: Clinical studies must establish the effectiveness and safety of these combinations, considering toxicity, disease progression, patient convenience, and cost.
Read the full article:
Title: Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies
Authors: Siamak Daneshmand, Stephen A. Boorjian, Joshua J. Meeks, Yair Lotan, Wassim Kassouf, Girish S. Kulkarni, Paolo Gontero, Peter Albers, Jørn S. Jakobsen, Kristian Juul
You may also be interested in:
Top 10 GU Oncology Updates: August–September 2026
